Literature DB >> 9270023

Loss of heterozygosity analysis in primary mammary tumors and lung metastases of MMTV-MTAg and MMTV-neu transgenic mice.

S R Ritland1, G J Rowse, Y Chang, S J Gendler.   

Abstract

Loss of heterozygosity (LOH) analysis has been used in many types of human cancer to localize putative tumor suppressor genes important in carcinogenesis. However, this approach has only recently been applied to transgenic mouse tumor models, which offer greater opportunity for detailed molecular genetic analysis of tumor initiation and progression. To explore the possible role of secondary genetic events in transgenic mouse mammary tumor development, we performed microsatellite-based allelotypes on primary mammary adenocarcinomas and lung metastases arising in mice transgenic for the polyomavirus middle T antigen under the control of the mouse mammary tumor virus promoter/enhancer (MMTV-MTAg mice) and on primary mammary adenocarcinomas arising in mice transgenic for the neu proto-oncogene (MMTV-neu mice). We examined a total of 80 microsatellite loci distributed throughout the mouse genome for LOH and observed high rates of specific chromosomal loss but very low rates of background allelic loss in these tumors. For the MMTV-MTAg mice, no individual chromosomes showed rates of LOH significantly above the background rates. For MMTV-neu mice, markers on chromosome 4 showed LOH in 82% of mammary tumors, whereas markers on chromosome 3 showed loss in 29% of tumors. These data suggest that the middle T antigen transgenic mice do not undergo whole chromosome loss or large genomic deletions as common mechanisms of tumor formation and that chromosomes 3 and 4 may contain tumor suppressor gene loci that play important roles in the development of neu-mediated mouse mammary tumors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9270023

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

Review 1.  Lessons in signaling and tumorigenesis from polyomavirus middle T antigen.

Authors:  Michele M Fluck; Brian S Schaffhausen
Journal:  Microbiol Mol Biol Rev       Date:  2009-09       Impact factor: 11.056

2.  Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel.

Authors:  Kimberly J Bussey; Koei Chin; Samir Lababidi; Mark Reimers; William C Reinhold; Wen-Lin Kuo; Fuad Gwadry; Hosein Kouros-Mehr; Jane Fridlyand; Ajay Jain; Colin Collins; Satoshi Nishizuka; Giovanni Tonon; Anna Roschke; Kristen Gehlhaus; Ilan Kirsch; Dominic A Scudiero; Joe W Gray; John N Weinstein
Journal:  Mol Cancer Ther       Date:  2006-04       Impact factor: 6.261

3.  The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis.

Authors:  M D Sternlicht; A Lochter; C J Sympson; B Huey; J P Rougier; J W Gray; D Pinkel; M J Bissell; Z Werb
Journal:  Cell       Date:  1999-07-23       Impact factor: 41.582

4.  Limitations of a murine transgenic breast cancer model for studies of erythropoietin-induced tumor progression.

Authors:  Chris P Miller; Karine Valliant-Saunders; Carl Anthony Blau
Journal:  Transl Oncol       Date:  2010-06-01       Impact factor: 4.243

Review 5.  The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter.

Authors:  M D Sternlicht; M J Bissell; Z Werb
Journal:  Oncogene       Date:  2000-02-21       Impact factor: 9.867

Review 6.  Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic.

Authors:  R M Hoffman
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

Review 7.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-04-30       Impact factor: 9.867

8.  Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells.

Authors:  Dongshu Chen; Jianchuan Xia; Yasuhiro Tanaka; Hongsong Chen; Shigeo Koido; Oliver Wernet; Pinku Mukherjee; Sandra J Gendler; Donald Kufe; Jianlin Gong
Journal:  Immunology       Date:  2003-06       Impact factor: 7.397

9.  Epithelial and fibroblast cell lines derived from a spontaneous mammary carcinoma in a MMTV/neu transgenic mouse.

Authors:  Michael J Campbell; Wendy S Wollish; Margaret Lobo; Laura J Esserman
Journal:  In Vitro Cell Dev Biol Anim       Date:  2002-06       Impact factor: 2.416

10.  Heterogeneity of mammary lesions represent molecular differences.

Authors:  Ruria Namba; Jeannie E Maglione; Ryan R Davis; Colin A Baron; Stephenie Liu; Condie E Carmack; Lawrence J T Young; Alexander D Borowsky; Robert D Cardiff; Jeffrey P Gregg
Journal:  BMC Cancer       Date:  2006-12-05       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.